Hyperhomocysteinemia and MTHFR Polymorphisms as Antenatal Risk Factors of White Matter Abnormalities in Two Cohorts of Late Preterm and Full Term Newborns
Table 1
Demographic, clinical, biochemical, neuroimaging and frequency features of the MTHFR genotypes. All genotypes were in Hardy-Weinberg equilibrium.
Patients
Sex (%)
81 M (47.4%)
Gestational age
≥37
126 (73.7%)
<37
45 (26.3%)
Type of pregnancy
Physiologic
104/171 (60.8%)
Pathologic
67/171 (39.2%)
Single
157/171 (91.8%)
Twin
14/171 (8.2%)
Drugs’ intake during gestation
Steroid
33/171 (19.3%)
Tocolytics
23/171 (13.5%)
Progestins
47/171 (27.5%)
Antiaggregant and/or anticoagulant
4/171 (2.3%)
Antenatal complications
Preeclampsia
5/171 (2.9%)
PROM
3/171 (1.8%)
Perinatal complications
Fetal bradycardia
18/171 (10.5%)
Flussimetry
6/171 (3.5%)
Meconium-stained liquor
3/171 (1.7%)
Neonatal complications
Apgar score (1 min)
8.25 (SD ± 1.7)
Apgar score (5 min)
9.35 (SD ± 1.1)
Birth weight (percentile)
48.95 (SD ± 28.1)
Perinatal infections
10/171 (5.8%)
Neonatal seizures
5/171 (2.9%)
Neuroimaging findings
WMA
36/171 (21.1%)
Ventricular Dilatation
6/36 (16.6%)
BGT
2/171 (1.1%)
IVH Grade I-II
13/171 (7.6%)
Ventriculo-Peritoneal shunt catheter
6/13 (46.1%)
tHcy µM/L (mean ± SD)
≥37 GA
9.74 (SD ± 3.98)
<37 GA
10.55 (SD ± 4.29)
Frequency of MTHFR C677T and A1298C genotypes ( pts)
≥37 wks ( = 38)
MTHFR677
19CT (50%)
4TT (10.5%)
MTHFR1298
6AC (15.7%)
1CC (2.6%)
<37 wks ()
MTHFR677
25CT (64.1%)
4TT (10.2%)
MTHFR1298
20AC (51.2%)
1CC (2.5%)
GA: gestational age; tHcy: total homocysteine; MTHFR: methylenetetrahydrofolate reductase; SD: standard deviation; WMA: white matter abnormalities; BGT: basal ganglia/thalamus; IVH: intraventricular haemorrhage.
